-
Guardant Health and Boehringer Ingelheim Join Forces to Develop Guardant360 CDx for Zongertinib Companion Diagnostic
•
US-based precision oncology specialist Guardant Health, Inc. (NASDAQ: GH) has entered into an agreement with German pharmaceutical giant Boehringer Ingelheim (BI) to jointly develop and commercialize Guardant360 CDx liquid biopsy as a companion diagnostic (CDx) for zongertinib. This collaboration aims to enhance the treatment landscape for non-small cell lung cancer…
-
AnHeart Therapeutics Partners with Guardant Health for Taletrectinib Diagnostics
•
Sino-US biopharma AnHeart Therapeutics and US precision oncology firm Guardant Health Inc. (NASDAQ: GH) have unveiled a partnership under which Guardant will provide companion diagnostics in support of AnHeart’s taletrectinib. This collaboration aims to enhance the development, regulatory approval, and commercialization of Guardant360 CDx and Guardant360 TissueNext assays in the…
